A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancerHenry Gómez, G. W. Sledge, Miguel A. Chavez et al.|Journal of Clinical Oncology|2005Cited by 72
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Fabrice André, Komal Jhaveri, Bogdan Żurawski et al.|Journal of Clinical Oncology|2024Cited by 32
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancerHenry Gómez, Adrián Martín, Miguel A. Chavez et al.|Journal of Clinical Oncology|2007Cited by 11
Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07)Erika Hamilton, Fabrice André, Komal Jhaveri et al.|Cancer Research|2023Cited by 5